The antitumor activity of dacomitinib was evaluated in a prespecified cohort of a phase II study, which included patients with advanced or metastatic NSCLC and HER2 mutations (n = 26) or amplification (n = 4) [60]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.